The company has launched the product in two strengths 20mg/1100mg and 40mg/1100mg capsules
Ajanta Pharma has received final approval from US FDA and is slated to launch omeprazole and sodium bicarbonate capsules in the US market, through its wholly owned subsidiary Ajanta Pharma USA. It is a bioequivalent prescription generic version of Zegerid and the company has launched the product in two strengths 20mg/1100mg and 40mg/1100mg capsules.
In total, Ajanta has 26 Abbreviated New Drug Application (ANDA) of which it has final approvals for 11 ANDAs; tentative approvals for one ANDA; and 14 ANDAs are under review with US FDA.